IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
VERIDIAN BIOSCIENCES, INC., a Delaware corporation,
Plaintiff,
v.
PENTERRA PHARMACEUTICALS CORP., a Delaware corporation,
Defendant.
C.A. No. 2024-___
DEFENDANT PENTERRA PHARMACEUTICALS CORP.'S ANSWER TO COMPLAINT AND AFFIRMATIVE DEFENSES
Date: November 1, 2024 Matter Number: 1018-00008
Prepared by:
Calderwood & Harkness LLP 200 Park Avenue, 42nd Floor New York, NY 10166 Telephone: (212) 558-4000 Facsimile: (212) 558-3588
Oliver Mackenzie (Partner, M&A) — Responsible Partner Harrison Wexford (Partner, M&A) — Billing Partner Megan Chu (Associate, M&A) — Lead Associate Derek Okonkwo (Associate, M&A) — Working Associate
Attorneys for Defendant Penterra Pharmaceuticals Corp.
TABLE OF CONTENTS
Right-click to update Table of Contents
PRELIMINARY STATEMENT
Defendant Penterra Pharmaceuticals Corp. ("Penterra" or "Defendant"), a Delaware corporation publicly traded on the Nasdaq Stock Market (ticker symbol: PPCA), with its principal executive office located at 1100 Meridian Boulevard, Suite 400, Princeton, New Jersey 08540, by and through its undersigned counsel, Calderwood & Harkness LLP, respectfully submits this Answer to the Verified Complaint (the "Complaint") filed by Plaintiff Veridian Biosciences, Inc. ("Veridian" or "Plaintiff") in the above-captioned action. In support thereof, Penterra states as follows:
This case is not, as Veridian would have the Court believe, a case of buyer's remorse. It is, rather, a straightforward case of a buyer properly exercising its contractual termination rights following a catastrophic and unforeseeable clinical trial failure that destroyed the fundamental value proposition underlying a negotiated acquisition agreement.
On June 10, 2024, Penterra and Veridian entered into a Stock Purchase Agreement (the "SPA") pursuant to which Penterra agreed to acquire one hundred percent (100%) of the outstanding capital stock of Veridian for an aggregate cash purchase price of Nine Hundred Million Dollars ($900,000,000). The SPA was the product of extensive arms'-length negotiations between sophisticated parties represented by experienced legal and financial advisors. As part of those negotiations, the parties agreed upon detailed closing conditions, a carefully constructed definition of "material adverse effect" (or "MAE"), and express termination provisions — each of which was designed to allocate specific risks between buyer and seller during the interim period between signing and closing.
Between signing and the anticipated closing, the precise risk that the MAE definition was negotiated to address materialized with devastating force. On August 14, 2024, the independent Data Monitoring Committee (the "DMC") for the Marlowe Asset Management-2 Phase II clinical trial of VRD-4187 — Veridian's lead drug candidate, a bispecific T-cell engager (BiTE) targeting DLL3-expressing tumors in small cell lung cancer ("SCLC") — completed its planned interim analysis and reported profoundly adverse safety and efficacy results. Specifically:
• The incidence of Grade 3 or higher cytokine release syndrome ("CRS") in the VRD-4187 treatment arm was 23.4%, compared to only 4.1% in the standard-of-care control arm — a differential of 19.3 percentage points representing a nearly six-fold increase in severe CRS events.
• Seven (7) treatment-related deaths occurred in the VRD-4187 arm (3.6% of 194 evaluable patients), compared to one (1) death in the control arm (0.5% of 193 evaluable patients).
• The overall response rate ("ORR") for VRD-4187 was 31.4%, compared to 28.9% for the control arm. This difference was not statistically significant (p = 0.58), demonstrating that VRD-4187 provided no meaningful efficacy benefit over standard-of-care therapy while subjecting patients to dramatically elevated safety risks.
The DMC recommended immediate suspension of enrollment and mandatory dose modification. Eight days later, on August 22, 2024, the United States Food and Drug Administration (the "FDA") imposed a partial clinical hold on VRD-4187 under Investigational New Drug Application No. 154832 (IND 154832), halting all further patient enrollment in the Marlowe Asset Management-2 trial.
These developments were devastating. Veridian is a clinical-stage biotechnology company with zero revenue — it reported total revenue of $0 for fiscal year 2023, a net loss of $87.3 million, and its entire enterprise value was predicated overwhelmingly on the clinical and commercial potential of VRD-4187, its lead pipeline asset. The Marlowe Asset Management-2 data did not merely represent a temporary setback or a routine clinical trial disappointment; it exposed fundamental problems with VRD-4187's pharmacological profile that called into question whether the drug candidate could ever achieve a viable risk-benefit profile suitable for regulatory approval. These are precisely the types of durable, company-specific adverse developments that the MAE definition was designed to capture.
Penterra acted in good faith and in strict compliance with the SPA's contractually prescribed procedures. On September 6, 2024, Penterra delivered a Deficiency Notice to Veridian identifying the material adverse effect and the resulting failure of the closing conditions set forth in SPA Sections 7.2(a) and 7.2(b). Penterra afforded Veridian the full cure period contemplated by the SPA. No cure was forthcoming — nor could one be forthcoming, given the nature and severity of the clinical findings and the FDA clinical hold. On September 27, 2024, Penterra's Board of Directors authorized the termination of the SPA. On September 30, 2024, Penterra delivered a formal Termination Notice to Veridian and to David Ng, in his capacity as Stockholder Representative, terminating the SPA pursuant to Section 8.1(d), well in advance of the Outside Date of December 10, 2024.
Veridian's claims for breach of contract and specific performance are without merit. The termination was a lawful exercise of express contractual rights triggered by the occurrence of an undeniable material adverse effect. Penterra is entitled to a judgment in its favor dismissing the Complaint in its entirety, and a declaration that the termination was valid, that a material adverse effect occurred, and that Penterra has no further obligations to Veridian, the Sellers, or the Stockholder Representative under the SPA.
NATURE OF THE ACTION
1. This action arises from the terminated acquisition of Veridian Biosciences, Inc. by Penterra Pharmaceuticals Corp. pursuant to a Stock Purchase Agreement dated June 10, 2024. Under the terms of the SPA, Penterra agreed to acquire one hundred percent (100%) of the outstanding capital stock of Veridian for an aggregate all-cash purchase price of Nine Hundred Million Dollars ($900,000,000).
2. The SPA was executed on June 10, 2024 by Dr. Anand Rajagopal, Chief Executive Officer of Penterra, on behalf of Penterra, and by Dr. Julian Marek, Chief Executive Officer and Co-Founder of Veridian, on behalf of Veridian and the selling stockholders.
3. Veridian is a privately held, clinical-stage biotechnology company headquartered at 550 Gateway Drive, Cambridge, Massachusetts 02142. Veridian has never generated any revenue from product sales. For its fiscal year ended December 31, 2023, Veridian reported total revenue of zero dollars ($0) and a net loss of eighty-seven million three hundred thousand dollars ($87,300,000). Veridian's principal asset — and the overwhelming driver of the nine hundred million dollar valuation reflected in the SPA — is its pipeline of immuno-oncology drug candidates developed on its proprietary VeriTCE bispecific T-cell engager platform. The most advanced and most critical of those candidates is VRD-4187, a bispecific antibody targeting DLL3-expressing tumors in patients with small cell lung cancer.
4. Between the signing of the SPA on June 10, 2024 and the anticipated closing, the Marlowe Asset Management-2 Phase II randomized clinical trial of VRD-4187 (ClinicalTrials.gov Identifier: NCT05837291), which enrolled a total of 387 patients across 42 clinical sites in the United States and the European Union, produced devastating safety and efficacy data. As described in detail in the Preliminary Statement and throughout this Answer, the interim analysis conducted by the independent DMC on August 14, 2024 revealed a dramatically elevated incidence of severe cytokine release syndrome, a statistically significant increase in treatment-related deaths, and no statistically significant efficacy benefit over standard-of-care therapy in the treatment arm. The FDA subsequently imposed a partial clinical hold on VRD-4187 on August 22, 2024.
5. These developments fundamentally altered Veridian's value proposition and constituted a material adverse effect within the meaning of Section 1.1 of the SPA. As a result, the conditions to Penterra's obligation to close set forth in SPA Sections 7.2(a) and 7.2(b) were not satisfied and were incapable of being satisfied prior to the Outside Date.
6. On September 30, 2024, Penterra exercised its contractual right to terminate the SPA pursuant to Section 8.1(d), delivering a formal Termination Notice to Veridian and to the Stockholder Representative. The termination was effected well in advance of the Outside Date of December 10, 2024.
7. Exclusive jurisdiction over this dispute lies in this Court pursuant to SPA Section 10.6, and the governing law is the law of the State of Delaware pursuant to the same section. Penterra does not contest personal jurisdiction or venue and submits to the jurisdiction of this Court.
PARTIES
A. Plaintiff
8. Veridian Biosciences, Inc. is a corporation organized and existing under the laws of the State of Delaware, with its principal office located at 550 Gateway Drive, Cambridge, Massachusetts 02142.
9. Veridian's registered agent in the State of Delaware is Tidewater Registered Agents LLC, 838 Walker Road, Suite 21-2, Dover, Delaware 19904.
10. Veridian's federal Employer Identification Number is 84-2193047.
11. Veridian's Chief Executive Officer and Co-Founder is Dr. Julian Marek, who is also an equity holder of Veridian holding approximately 8.4% of the outstanding capital stock. Veridian's Chief Scientific Officer and Co-Founder is Dr. Priya Chandrasekaran, who holds approximately 6.2% of the outstanding capital stock. Veridian's Chief Financial Officer is Steven R. Kessler, and its General Counsel is Rachel Stein-Goldberg.
12. Veridian is represented in this action by Zalcourt Archer & Cole LLP, with Rebecca Whitmore serving as Lead Partner. Zalcourt Archer & Cole LLP is located at One Federal Street, 30th Floor, Boston, Massachusetts 02110.
13. Veridian's financial advisor in connection with the transaction that is the subject of this action was Ridgeway Partners LLC, with Laura Beckett, Managing Director, serving as the principal contact. Ridgeway Partners LLC is located at 101 Huntington Avenue, Suite 2500, Boston, Massachusetts 02199.
14. The Stockholder Representative appointed under the SPA is David Ng, Managing Partner of Crestline Ventures, LP. Mr. Ng was designated to act as the Stockholder Representative on behalf of the selling stockholders of Veridian following the execution of the SPA.
B. Defendant
15. Penterra Pharmaceuticals Corp. is a corporation organized and existing under the laws of the State of Delaware, with its principal executive office located at 1100 Meridian Boulevard, Suite 400, Princeton, New Jersey 08540.
16. Penterra's registered agent in the State of Delaware is Capitol Corporate Services, Inc., 1675 South Ashbury Asset Advisors, Suite B, Dover, Delaware 19901.
17. Penterra is a publicly traded company, with its common stock listed on the Nasdaq Stock Market under the ticker symbol "PPCA." As of June 2024, Penterra's approximate market capitalization was Fourteen Billion Two Hundred Million Dollars ($14,200,000,000).
18. Penterra's federal Employer Identification Number is 22-3847561.
19. Penterra's Chief Executive Officer is Dr. Anand Rajagopal. Its Chief Financial Officer is Catherine M. Burgess. Its General Counsel and Secretary is Thomas F. Holbrook. Its Senior Vice President, Corporate Development is Natalie Reiner. The Chair of Penterra's Board of Directors is Margaret Liu Whitfield.
20. For its fiscal year ended December 31, 2023, Penterra reported total revenue of Four Billion Eight Hundred Seventy Million Dollars ($4,870,000,000). As of the end of the second quarter of 2024 (June 30, 2024), Penterra had cash and cash equivalents on hand of approximately Two Billion One Hundred Million Dollars ($2,100,000,000).
ANSWER TO SPECIFIC ALLEGATIONS OF THE COMPLAINT
Penterra answers each numbered paragraph of the Complaint as follows. To the extent any allegation of the Complaint is not specifically addressed below, it is denied. All references to the SPA and other written instruments are qualified by the statement that those documents speak for themselves, and Penterra denies any characterization of those documents that is inconsistent with their actual terms.
I. Responses to Allegations Concerning the Parties (Complaint ¶¶ 1–15)
21. Penterra admits that it is a corporation organized and existing under the laws of the State of Delaware. Penterra admits that Veridian is a corporation organized and existing under the laws of the State of Delaware. Penterra admits the corporate existence and good standing of both Penterra and Veridian, in each case as of the relevant dates alleged in the Complaint.
22. To the extent the Complaint sets forth the identities, titles, and positions of the key officers, directors, and representatives of Penterra and Veridian, Penterra admits those allegations as factual matters of public record and corporate documentation, except that Penterra denies any characterizations or inferences drawn from the identification of such individuals that are inconsistent with the factual record.
23. Penterra admits that it is a publicly traded company listed on the Nasdaq Stock Market under the ticker symbol "PPCA" and that its approximate market capitalization was $14.2 billion as of June 2024.
24. Penterra admits that Veridian is a privately held, clinical-stage biotechnology company with its principal office at 550 Gateway Drive, Cambridge, Massachusetts 02142, and that Veridian's registered agent is Tidewater Registered Agents LLC at the address stated in the Complaint.
25. To the extent the Complaint alleges any additional facts concerning the parties beyond those admitted herein, Penterra denies such allegations unless they are specifically admitted elsewhere in this Answer.
II. Responses to Allegations Concerning the Transaction Background (Complaint ¶¶ 16–45)
26. Penterra admits the existence of the Stock Purchase Agreement dated June 10, 2024. Penterra admits that the aggregate cash purchase price set forth in the SPA was Nine Hundred Million Dollars ($900,000,000). Penterra states that the SPA speaks for itself, and Penterra denies any characterizations of the SPA or its terms that are inconsistent with the actual language of the agreement.
27. Penterra admits that on or about February 12, 2024, the Board of Directors of Penterra authorized the exploration of a potential acquisition of Veridian. Penterra admits that this authorization followed a strategic review conducted by Penterra's senior management and Corporate Development team, led by Natalie Reiner, Senior Vice President, Corporate Development.
28. Penterra admits that on or about February 14, 2024, Penterra engaged Calderwood & Harkness LLP as its legal advisor and Garrison Zanthor & Co., LLC as its financial advisor in connection with the proposed transaction.
29. Penterra admits that a non-binding indication of interest (the "IOI") was submitted to Veridian on or about March 1, 2024. The IOI set forth an indicative enterprise value range of Eight Hundred Fifty Million Dollars ($850,000,000) to Nine Hundred Fifty Million Dollars ($950,000,000), subject to confirmatory due diligence and other customary conditions.
30. Penterra admits that a mutual non-disclosure agreement (the "NDA") was executed between Penterra and Veridian on or about March 4, 2024. Penterra further admits that access to Veridian's electronic data room was granted to Penterra and its advisors on or about March 11, 2024.
31. Penterra admits that on or about March 18, 2024, Penterra engaged Broadleaf Scientific Consulting LLC to conduct independent clinical due diligence on Veridian's pipeline, including specifically VRD-4187 and the Marlowe Asset Management-2 trial program. The engagement was led by Dr. Raymond Kapoor, a recognized expert in oncology clinical trial design and regulatory science.
32. Penterra admits that a Premerger Notification and Report Form pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), was filed with the Federal Trade Commission and the Antitrust Division of the United States Department of Justice on or about April 22, 2024. The filing fee paid was Two Hundred Eighty Thousand Five Hundred Dollars ($280,500). Early termination of the HSR waiting period was granted on May 20, 2024. Penterra's antitrust counsel for the HSR filing was Stonebridge HSW Antitrust Advisors LLP, with Martin Prumvane serving as lead partner.
33. Penterra admits that on or about June 7, 2024, a financing commitment letter (Reference No. CL-2024-PPCA-0607) was executed with Summit Ridge Capital Partners, LP and Ironclad Trust Company, N.A. The commitment letter provided for a Five Hundred Million Dollar ($500,000,000) senior secured term loan at a rate of SOFR plus 225 basis points, subject to customary conditions. This financing, together with Penterra's available cash on hand, was sufficient to fund the full purchase price under the SPA.
34. Penterra admits that Garrison Zanthor & Co., LLC delivered a fairness opinion to the Penterra Board of Directors on June 9, 2024, opining that the purchase price of $900,000,000 was fair, from a financial point of view, to Penterra. The fairness opinion was presented by Kevin Driscoll, Managing Director of Garrison Zanthor.
35. Penterra admits that the Board of Directors of Penterra ratified and authorized the execution and delivery of the SPA at a meeting held on June 10, 2024.
36. Penterra admits, upon information and belief, that Veridian obtained written consents from holders of more than ninety percent (90%) of its outstanding capital stock approving the transaction, and that such written consents were delivered on or about June 14, 2024.
37. Penterra admits that a representations and warranties insurance policy (Policy No. AIC-RWI-2024-07892) was bound with Atlas Indemnity Insurance Co. on or about June 12, 2024. Penterra admits that the policy had a limit of liability of One Hundred Eighty Million Dollars ($180,000,000), a self-insured retention ("SIR") of Nine Million Dollars ($9,000,000), an annual premium of Three Million Nine Hundred Sixty Thousand Dollars ($3,960,000), and an underwriting fee of Seventy-Five Thousand Dollars ($75,000). Penterra admits that the policy was brokered by Prescott Whitfield Insurance Brokers, Inc., with Amanda Chen-Kowalski serving as the responsible broker.
38. To the extent the Complaint contains additional allegations or characterizations concerning the transaction background beyond those specifically admitted above, Penterra states that the SPA, the IOI, the NDA, the commitment letter, the fairness opinion, the R&W insurance policy, and all other referenced documents speak for themselves, and Penterra denies any characterizations of such documents that are inconsistent with their actual terms.
III. Responses to Allegations Concerning SPA Terms (Complaint ¶¶ 46–78)
39. Penterra admits that the SPA contained the following key economic terms, and states that the SPA speaks for itself in all respects:
(a) Purchase Price: Nine Hundred Million Dollars ($900,000,000), as set forth in SPA Section 2.1.
(b) Indemnification Escrow Amount: One Hundred Eighty Million Dollars ($180,000,000), representing twenty percent (20%) of the purchase price, to be deposited with Fidelis National Escrow Corp. (Brian Mulcahy, Senior Vice President), as set forth in SPA Section 2.3.
(c) Stockholder Representative Expense Fund: Two Million Five Hundred Thousand Dollars ($2,500,000), as set forth in SPA Section 2.3(b).
(d) Net Closing Payment (Had Closing Occurred): Seven Hundred Seventeen Million Five Hundred Thousand Dollars ($717,500,000), calculated as the purchase price less the indemnification escrow amount and the stockholder representative expense fund.
(e) Indemnification Cap (General): One Hundred Eighty Million Dollars ($180,000,000), representing twenty percent (20%) of the purchase price.
(f) Indemnification Basket: Nine Million Dollars ($9,000,000), representing one percent (1%) of the purchase price, structured as a tipping basket, as set forth in SPA Section 9.2.
(g) Special/Fundamental Representations Cap: Nine Hundred Million Dollars ($900,000,000), representing one hundred percent (100%) of the purchase price.
(h) Survival Period for General Representations: Eighteen (18) months following the Closing Date.
(i) Survival Period for Fundamental and Tax Representations: The full applicable statute of limitations plus sixty (60) days.
(j) Reverse Termination Fee: Forty-Five Million Dollars ($45,000,000), representing five percent (5%) of the purchase price, triggered only in the event of a failure of Buyer's financing.
(k) Target Termination Fee: Thirty-Six Million Dollars ($36,000,000), representing four percent (4%) of the purchase price, triggered only in the event of a breach by the Company of the no-shop covenant.
(l) No-Shop Provision: SPA Section 5.4, providing for a prohibition on solicitation of competing proposals, with four (4) business-day matching rights for Penterra in the event of an unsolicited Superior Proposal (as defined in the SPA).
(m) Exclusive Jurisdiction: The Court of Chancery of the State of Delaware, as set forth in SPA Section 10.6.
(n) Governing Law: The law of the State of Delaware, as set forth in SPA Section 10.6.
40. Penterra admits that SPA Section 1.1 defines "Material Adverse Effect" (or "MAE") as any event, change, development, occurrence, condition, or effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of operations, financial condition, or assets of the Company, taken as a whole, or (b) the ability of the Sellers to consummate the Transactions. The SPA speaks for itself as to the precise language and scope of this definition.
41. Penterra admits that the MAE definition in SPA Section 1.1 contains carveouts for the following categories of events, changes, developments, occurrences, conditions, or effects:
(i) general economic or political conditions;
(ii) conditions affecting the biotechnology or pharmaceutical industries generally;
(iii) changes in applicable law or in United States generally accepted accounting principles ("GAAP");
(iv) pandemics, including COVID-19 and similar public health emergencies;
(v) natural disasters, acts of war, or terrorism;
(vi) changes in financial markets generally; and
(vii) the announcement or pendency of the Transactions.
42. Penterra admits that the carveouts set forth in clauses (i) through (vi) above are subject to a disproportionate-impact exception. Specifically, the carveouts do not apply — and the relevant events, changes, or developments may be taken into account in determining whether an MAE has occurred — to the extent that the applicable event, change, or development disproportionately affects the Company relative to comparably situated companies operating in the biotechnology industry.
43. Penterra admits that the SPA contains a specific performance provision at Section 10.12 that grants the Sellers the right to seek specific performance to compel the Buyer to consummate the closing, provided that all closing conditions are satisfied. The SPA speaks for itself as to the precise terms and conditions of this provision.
44. Penterra denies any characterization in the Complaint that all closing conditions were satisfied at the time of Penterra's termination of the SPA, or at any time following the events described herein. As set forth in this Answer and in the Affirmative Defenses below, the closing conditions in SPA Sections 7.2(a) and 7.2(b) were not satisfied and were incapable of being satisfied.
IV. Responses to Allegations Concerning the Closing Conditions (Complaint ¶¶ 79–87)
45. Penterra admits that SPA Section 7.2(a) provides that, as a condition to Buyer's obligation to consummate the closing, the representations and warranties of the Sellers set forth in the SPA (other than Fundamental Representations) shall be true and correct in all respects (without giving effect to any materiality or MAE qualifiers therein) as of the date of the SPA and as of the Closing Date as though made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date), except where the failures of such representations and warranties to be so true and correct would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
46. Penterra admits that SPA Section 7.2(b) provides that, as a separate condition to Buyer's obligation to consummate the closing, since the date of the Agreement, no Material Adverse Effect shall have occurred that is continuing as of the Closing Date.
47. Penterra denies that these conditions were satisfied or capable of being satisfied at the time of Penterra's termination or at any time thereafter prior to the Outside Date of December 10, 2024. The occurrence of the material adverse effect described herein rendered both Section 7.2(a) and Section 7.2(b) incapable of satisfaction.
V. Responses to Allegations Concerning VRD-4187 Clinical Data and FDA Action (Complaint ¶¶ 88–120)
48. Penterra admits that on August 14, 2024, the independent Data Monitoring Committee for the Marlowe Asset Management-2 Phase II randomized clinical trial of VRD-4187 (ClinicalTrials.gov Identifier: NCT05837291) completed its pre-planned interim analysis. Penterra admits that the Marlowe Asset Management-2 trial enrolled a total of 387 patients across 42 clinical sites in the United States and the European Union.
49. Penterra admits that the DMC recommended the immediate suspension of enrollment in the Marlowe Asset Management-2 trial and mandatory dose modification for VRD-4187 as a result of the interim analysis findings.
50. Penterra admits that it received notice of the DMC findings from Veridian on August 16, 2024, two (2) days after the August 14, 2024 DMC meeting. Veridian provided such notice pursuant to SPA Section 5.1(b), which requires the Company to provide prompt notice to Buyer of any material developments affecting the Company's business, operations, or clinical programs.
51. Penterra admits the following specific clinical data findings from the Marlowe Asset Management-2 interim analysis, as reported by the DMC:
(a) The incidence of Grade 3 or higher cytokine release syndrome (CRS) in the VRD-4187 treatment arm was 23.4%, compared to 4.1% in the standard-of-care control arm — a differential of 19.3 percentage points.
(b) Seven (7) treatment-related deaths occurred in the VRD-4187 treatment arm, representing 3.6% of the 194 evaluable patients in that arm. One (1) treatment-related death occurred in the control arm, representing 0.5% of the 193 evaluable patients in that arm.
(c) The overall response rate (ORR) was 31.4% in the VRD-4187 arm and 28.9% in the control arm. The difference was not statistically significant (p = 0.58), indicating no meaningful efficacy benefit of VRD-4187 over standard-of-care therapy.
52. Penterra admits that on August 22, 2024, the FDA imposed a partial clinical hold on VRD-4187 under Investigational New Drug Application No. 154832 (IND 154832). The partial clinical hold halted further enrollment of new patients in the Marlowe Asset Management-2 trial and required Veridian to submit additional safety data and a revised clinical protocol before enrollment could resume.
53. Penterra admits, upon information and belief, that Veridian implemented a Protocol v4.0 amendment on or about August 28, 2024, which included mandatory tocilizumab prophylaxis for all patients receiving VRD-4187 and a dose reduction from 1.5 mg/kg to 0.75 mg/kg — effectively halving the therapeutic dose.
54. Penterra admits that Broadleaf Scientific Consulting LLC delivered a supplemental clinical assessment to Penterra on August 19, 2024. The supplemental assessment was prepared by Dr. Raymond Kapoor and his team at Broadleaf Scientific at Penterra's request following receipt of the DMC interim analysis results.
55. Penterra denies any characterization in the Complaint that the Marlowe Asset Management-2 clinical data was preliminary, routine, expected, or non-material. The data represented a definitive and catastrophic readout from the critical value-driving clinical program for Veridian's lead drug candidate, revealing fundamental safety and efficacy problems of the most serious kind.
56. Penterra denies that the Protocol v4.0 amendment, any other mitigation effort undertaken or proposed by Veridian, or any other development occurring after August 14, 2024 cured, remediated, or was reasonably expected to cure or remediate the material adverse effect that had occurred. The Protocol v4.0 amendment — which mandated prophylactic tocilizumab administration and cut the VRD-4187 dose in half — is itself an acknowledgment by Veridian of the severity of the safety signal. A dose reduction of this magnitude would require entirely new dose-response and safety data to be generated over an extended period, with no assurance of success and under the cloud of an FDA clinical hold that remains in effect to this day. Such measures are not "cures" within any reasonable meaning of the term; they are fundamental redesigns of the clinical program necessitated by catastrophic safety findings.
VI. Responses to Allegations Concerning Penterra's Deficiency Notice and Termination (Complaint ¶¶ 121–145)
57. Penterra admits that on September 6, 2024, Penterra delivered a Deficiency Notice to Veridian pursuant to the SPA, identifying the occurrence of a material adverse effect within the meaning of SPA Section 1.1 and the resulting failure of the closing conditions set forth in SPA Sections 7.2(a) and 7.2(b). The Deficiency Notice was delivered in writing to Veridian's General Counsel, Rachel Stein-Goldberg, and to David Ng as Stockholder Representative, by both email and overnight courier, as required by the SPA.
58. Penterra admits that on September 13, 2024, Veridian responded to the Deficiency Notice in a letter from its outside counsel, Rebecca Whitmore of Zalcourt Archer & Cole LLP, disputing the occurrence of a material adverse effect and demanding that Penterra proceed to closing. Penterra denies the substance of Veridian's assertions in its September 13 response and avers that the response failed to identify any basis upon which the material adverse effect could be cured or the closing conditions could be satisfied.
59. Penterra admits that on September 27, 2024, the Board of Directors of Penterra authorized the termination of the SPA pursuant to SPA Section 8.1(d), upon the recommendation of management and outside counsel. The Board resolution authorizing termination was drafted by Calderwood & Harkness LLP and was adopted unanimously by the independent and disinterested members of the Board.
60. Penterra admits that on September 30, 2024, Penterra delivered a formal Termination Notice to Veridian and to David Ng, in his capacity as Stockholder Representative, terminating the SPA pursuant to Section 8.1(d). The Termination Notice was delivered in writing by both email and overnight courier to all persons entitled to notice under the SPA, including Veridian's General Counsel and outside counsel.
61. Penterra denies that the termination of the SPA was wrongful, that it constituted a breach of the SPA, or that it was undertaken in bad faith. To the contrary, the termination was a lawful exercise of Penterra's express contractual rights under SPA Section 8.1(d), undertaken in strict compliance with the notice, cure, and procedural requirements of the SPA.
62. Penterra affirmatively avers that the termination was proper under SPA Section 8.1(d) because the closing conditions in Sections 7.2(a) and 7.2(b) were incapable of being satisfied prior to the Outside Date of December 10, 2024 as a result of the occurrence of a material adverse effect with respect to Veridian's business, results of operations, financial condition, and assets, taken as a whole. The material adverse effect arose from the Marlowe Asset Management-2 clinical trial data, the DMC's recommendation, and the FDA's imposition of a partial clinical hold, as detailed herein.
VII. Responses to Allegations Concerning Damages (Complaint ¶¶ 146–165)
63. Penterra denies that Veridian has suffered any damages as a result of Penterra's termination of the SPA. The termination was lawful and was effected in accordance with Penterra's express contractual rights under the SPA. Veridian is not entitled to recover any damages — contractual, equitable, or otherwise — arising from a valid termination.
64. Penterra denies that Veridian is entitled to specific performance of the SPA. As set forth in greater detail in the Affirmative Defenses below, SPA Section 10.12 provides for specific performance only if all closing conditions are satisfied. The closing conditions in SPA Sections 7.2(a) and 7.2(b) were not satisfied. Accordingly, Veridian has no contractual right to specific performance.
65. Penterra denies that Veridian is entitled to expectation damages in the amount of Nine Hundred Million Dollars ($900,000,000) or in any other amount. To the extent Veridian seeks expectation damages measured by the full purchase price, such a claim is speculative, unsupported, and contrary to applicable law.
66. Penterra denies that the reverse termination fee of Forty-Five Million Dollars ($45,000,000) is applicable to the termination at issue in this case. Penterra affirmatively avers that the reverse termination fee, as set forth in the SPA, is triggered exclusively by a failure of the Buyer's financing — i.e., where the Buyer fails to consummate the closing because the financing contemplated by the SPA was not available. That is not what occurred here. Penterra's financing was fully committed and available: the Five Hundred Million Dollar ($500,000,000) term loan commitment from Summit Ridge Capital Partners, LP and Ironclad Trust Company, N.A. (Reference No. CL-2024-PPCA-0607) remained in full force and effect at the time of termination, and Penterra had Four Hundred Million Dollars ($400,000,000) of its own cash designated for the transaction from its total cash on hand of approximately Two Billion One Hundred Million Dollars ($2,100,000,000) as of the end of Q2 2024. The aggregate available funding of $900,000,000 was fully sufficient to pay the purchase price. The termination was not based on a financing failure; it was based on the failure of the closing conditions in Sections 7.2(a) and 7.2(b) due to the occurrence of a material adverse effect. The reverse termination fee is therefore inapplicable as a matter of contract.
67. Penterra reserves all rights to challenge Veridian's damage calculations, theories of recovery, and the legal and factual bases for any claimed damages, including but not limited to the right to contest the reasonableness, foreseeability, and mitigation of any alleged damages.
VIII. Responses to Allegations Concerning Veridian's Post-Termination Conduct (Complaint ¶¶ 166–175)
68. Penterra admits receipt of a demand letter dated October 15, 2024 from Zalcourt Archer & Cole LLP, acting on behalf of Veridian, threatening litigation for breach of contract and specific performance in the Court of Chancery of the State of Delaware.
69. Penterra denies all allegations of wrongful conduct by Penterra asserted in the Complaint or in any correspondence from Veridian or its counsel.
IX. General Denial
70. To the extent any allegation in the Complaint is not specifically admitted in this Answer, such allegation is hereby denied. Penterra denies each and every allegation of the Complaint that is not expressly and unequivocally admitted herein.
AFFIRMATIVE DEFENSES
Without admitting any burden of proof that would not otherwise be imposed upon it by law, and without waiving any argument that any of the following defenses need not be pleaded, Penterra asserts the following affirmative defenses to the claims asserted in the Complaint:
FIRST AFFIRMATIVE DEFENSE: Lawful Termination Under SPA § 8.1(d)
71. Veridian's claims are barred, in whole or in part, because Penterra lawfully and properly terminated the SPA on September 30, 2024 pursuant to SPA Section 8.1(d).
72. Section 8.1(d) of the SPA expressly provides that the Buyer may terminate the SPA if the conditions to Buyer's obligation to close set forth in Section 7.2 have not been satisfied (or, in Buyer's reasonable determination, are incapable of being satisfied) at or prior to the Outside Date of December 10, 2024, provided that such failure to satisfy the applicable closing conditions is not primarily the result of a breach by Buyer of any covenant, agreement, or obligation of Buyer under the SPA.
73. The conditions to Buyer's obligation to close set forth in SPA Sections 7.2(a) and 7.2(b) were not satisfied and, as of the date of the Termination Notice on September 30, 2024, were incapable of being satisfied prior to the Outside Date of December 10, 2024. The failure of these conditions was the direct and proximate result of the material adverse effect arising from the Marlowe Asset Management-2 clinical trial data, the DMC's recommendation, and the FDA's imposition of a partial clinical hold on VRD-4187 — events entirely outside of Penterra's control and unrelated to any action or inaction by Penterra.
74. Penterra was not in breach of any covenant, agreement, or obligation under the SPA at the time of termination or at any time prior thereto. Penterra complied fully with the procedural and substantive requirements of the SPA, including:
(a) Delivering the Deficiency Notice to Veridian and the Stockholder Representative on September 6, 2024, identifying the material adverse effect and the failure of closing conditions with specificity;
(b) Allowing Veridian the full thirty (30) day cure period contemplated by the SPA, during which no cure was forthcoming or possible;
(c) Obtaining authorization from the Penterra Board of Directors on September 27, 2024, following full deliberation and consideration of management's recommendation and outside counsel's advice; and
(d) Delivering the formal Termination Notice in proper form to Veridian and the Stockholder Representative (David Ng) on September 30, 2024.
75. Because Penterra exercised its termination right in full compliance with the express terms of the SPA, Veridian has no claim for breach of contract, specific performance, or any other remedy.
SECOND AFFIRMATIVE DEFENSE: Occurrence of a Material Adverse Effect
76. Veridian's claims are barred, in whole or in part, because a Material Adverse Effect occurred within the meaning of SPA Section 1.1 with respect to the business, results of operations, financial condition, and assets of Veridian, taken as a whole.
77. The Marlowe Asset Management-2 Phase II clinical trial data for VRD-4187 constitutes a Material Adverse Effect because:
(a) VRD-4187 Was Veridian's Lead and Most Valuable Pipeline Asset. VRD-4187 was the most advanced clinical candidate in Veridian's pipeline and the primary driver of the nine hundred million dollar valuation reflected in the SPA. The Marlowe Asset Management-2 trial was the critical, value-defining clinical program for both the drug candidate and the company as a whole.
(b) Veridian Is a Zero-Revenue Clinical-Stage Company. Veridian had no revenue in fiscal year 2023 and had never generated any revenue from product sales. Its net loss for fiscal year 2023 was $87.3 million. Its entire enterprise value was predicated overwhelmingly on the clinical and commercial potential of VRD-4187. When the clinical foundation for that potential collapsed, the fundamental value proposition of Veridian was destroyed.
(c) The Safety Signal Was Severe and Unprecedented. The 23.4% incidence of Grade 3 or higher cytokine release syndrome in the VRD-4187 treatment arm, compared to only 4.1% in the control arm — a differential of 19.3 percentage points — represents a nearly six-fold increase in the rate of severe CRS. This safety signal is not a marginal or borderline finding. It is a dramatic and clinically significant adverse finding that would be disqualifying for any drug candidate in a regulatory submission.
(d) Treatment-Related Deaths Were Significantly Elevated. Seven (7) treatment-related deaths occurred in the VRD-4187 arm (3.6% mortality rate) compared to one (1) death in the control arm (0.5% mortality rate). The seven-to-one differential in treatment-related mortality represents a profound safety concern that cannot be explained away as statistical noise or manageable risk.
(e) Efficacy Was Not Statistically Significant. The overall response rate of 31.4% for VRD-4187 was not statistically significantly different from the 28.9% ORR in the control arm (p = 0.58). This means that VRD-4187 imposed catastrophic safety risks on patients while delivering no demonstrable therapeutic benefit over existing standard-of-care therapies. A drug with a dramatically worse safety profile and no meaningful efficacy advantage has essentially no viable path to regulatory approval.
(f) The FDA Imposed a Partial Clinical Hold. The FDA's imposition of a partial clinical hold on VRD-4187 under IND 154832 on August 22, 2024 imposed a formal regulatory barrier to continued clinical development. Clinical holds are among the most serious regulatory actions the FDA can take with respect to an investigational drug, and the duration and ultimate outcome of the hold process are inherently uncertain.
(g) The Adverse Developments Are Durational, Not Temporary. The clinical trial findings and FDA clinical hold are not short-term fluctuations or temporary setbacks. They reflect fundamental, durable problems with VRD-4187's pharmacological profile — specifically, its propensity to cause severe cytokine release syndrome and treatment-related death at therapeutic doses. These are intrinsic characteristics of the drug candidate that cannot be "cured" by protocol amendments or dose modifications without fundamentally redesigning the clinical program, at enormous cost and with no assurance of success. The dose reduction from 1.5 mg/kg to 0.75 mg/kg, if anything, compounds the problem because it raises fundamental questions about whether VRD-4187 can achieve therapeutic efficacy at a dose that is tolerable. This is precisely the type of durational adverse development that Delaware law recognizes as constituting a material adverse effect. See Akorn, Inc. v. Fresenius Kabi AG, 2018 WL 4719347, at 53 (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018) (holding that a material adverse effect had occurred and that the buyer was entitled to terminate where, inter alia*, the target's business performance had suffered a "durationally significant" decline).
(h) The Combination of Safety, Efficacy, and Regulatory Failures Is Devastating. Viewed in the aggregate, the combination of catastrophic safety data, absence of efficacy benefit, regulatory intervention in the form of an FDA clinical hold, and the DMC's recommendation to suspend enrollment constitutes an event that has had, and would reasonably be expected to continue to have, a material adverse effect on Veridian's business, results of operations, financial condition, and assets, taken as a whole.
THIRD AFFIRMATIVE DEFENSE: Inapplicability of MAE Carveouts
78. Veridian's claims are barred, in whole or in part, because none of the MAE carveouts set forth in SPA Section 1.1, clauses (i) through (vii), apply to the events underlying the material adverse effect.
79. The Marlowe Asset Management-2 clinical trial results and the FDA partial clinical hold on VRD-4187 are not attributable to any of the categories of events carved out from the MAE definition:
(a) They are not attributable to general economic or political conditions (clause (i)). The clinical trial data is a product of VRD-4187's unique pharmacological characteristics and has no relationship to macroeconomic or political developments.
(b) They are not attributable to conditions affecting the biotechnology or pharmaceutical industries generally (clause (ii)). The VRD-4187 safety signal and efficacy failure are specific to Veridian's proprietary drug candidate. No industry-wide trend or condition caused the 23.4% Grade ≥3 CRS rate, the seven treatment-related deaths, or the non-significant ORR. Other companies developing bispecific T-cell engagers and immuno-oncology therapies were not similarly affected.
(c) They are not attributable to changes in applicable law or GAAP (clause (iii)). No change in law or accounting standards caused or contributed to the clinical trial results or the FDA clinical hold.
(d) They are not attributable to pandemics, including COVID-19 or similar public health emergencies (clause (iv)). No pandemic or public health emergency caused or contributed to the Marlowe Asset Management-2 data.
(e) They are not attributable to natural disasters, acts of war, or terrorism (clause (v)). No natural disaster, act of war, or act of terrorism caused or contributed to the clinical trial results.
(f) They are not attributable to changes in financial markets generally (clause (vi)). The clinical trial data has no connection to fluctuations in capital markets.
(g) They are not attributable to the announcement or pendency of the Transactions (clause (vii)). The SPA's signing and the announcement of the proposed acquisition did not cause or contribute to VRD-4187's safety failures or the FDA clinical hold.
80. The clinical data is a quintessentially company-specific event arising from the unique pharmacological properties, mechanism of action, and safety profile of VRD-4187 — Veridian's proprietary compound. The FDA partial clinical hold is a regulatory action directed specifically at VRD-4187 under IND 154832, not an industry-wide regulatory change affecting biotechnology or pharmaceutical companies generally.
81. Even if any carveout were arguably applicable (which Penterra denies), the disproportionate-impact exception would apply. The Marlowe Asset Management-2 clinical trial data and the FDA partial clinical hold disproportionately affect Veridian relative to comparably situated companies operating in the biotechnology industry, including other clinical-stage companies developing bispecific T-cell engager therapies. No other comparably situated company experienced analogous clinical trial failures or regulatory holds during the relevant period. The disproportionate-impact exception therefore ensures that these company-specific developments are properly considered in the MAE analysis.
FOURTH AFFIRMATIVE DEFENSE: Failure of Closing Conditions — Bring-Down of Representations (SPA § 7.2(a))
82. Veridian's claims are barred, in whole or in part, because the closing condition set forth in SPA Section 7.2(a) was not satisfied and was incapable of being satisfied.
83. Section 7.2(a) required that the Sellers' representations and warranties in the SPA be true and correct in all respects (disregarding materiality and MAE qualifiers) as of the Closing Date (or, if made as of a specific date, as of such date), except where the failures of such representations and warranties to be so true and correct would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
84. Following the Marlowe Asset Management-2 interim analysis on August 14, 2024 and the FDA partial clinical hold on August 22, 2024, multiple representations and warranties of the Sellers contained in the SPA were no longer true and correct, and the aggregate failures of such representations were of a character and magnitude that would reasonably be expected to have a Material Adverse Effect. The affected representations include, but are not limited to, representations and warranties concerning:
(a) the absence of material changes in the business, operations, financial condition, or assets of Veridian since the date of the most recent financial statements;
(b) the status and condition of Veridian's material clinical programs and regulatory filings, including the accuracy of information provided to Penterra regarding the Marlowe Asset Management-2 trial;
(c) compliance with applicable laws and regulations, including FDA regulations governing the conduct of clinical trials and reporting of adverse events; and
(d) the condition and value of Veridian's material assets, including its intellectual property portfolio and clinical-stage drug candidates.
85. The failure of SPA Section 7.2(a) constituted an independent basis upon which Penterra was entitled to decline to close and to terminate the SPA under Section 8.1(d), separate and apart from the failure of Section 7.2(b).
FIFTH AFFIRMATIVE DEFENSE: No Material Adverse Effect Condition (SPA § 7.2(b)) Not Satisfied
86. Veridian's claims are barred, in whole or in part, because the closing condition set forth in SPA Section 7.2(b) was not satisfied and was incapable of being satisfied.
87. Section 7.2(b) of the SPA required, as a separate and independent condition to Buyer's obligation to consummate the closing, that no Material Adverse Effect shall have occurred since the date of the Agreement (June 10, 2024) that was continuing as of the Closing Date.
88. A Material Adverse Effect did occur between June 10, 2024 and the date of the Termination Notice (September 30, 2024), and such Material Adverse Effect was continuing as of that date and would have been continuing as of any proposed Closing Date through the Outside Date of December 10, 2024. The basis for this determination is set forth in full in the Second Affirmative Defense above and is incorporated herein by reference.
89. The failure of SPA Section 7.2(b) constituted an independent basis upon which Penterra was entitled to decline to close and to terminate the SPA under Section 8.1(d), separate and apart from the failure of Section 7.2(a).
SIXTH AFFIRMATIVE DEFENSE: Specific Performance Unavailable — Closing Conditions Not Satisfied
90. Veridian is not entitled to specific performance of the SPA because the contractual prerequisites for such relief are not met.
91. SPA Section 10.12 provides that the Sellers may seek specific performance to compel the Buyer to consummate the closing only if "all closing conditions are satisfied." This is a condition precedent to the availability of the specific performance remedy, negotiated and agreed upon by the parties as part of the overall allocation of rights and remedies under the SPA.
92. As set forth in the Fourth and Fifth Affirmative Defenses above, the closing conditions in SPA Sections 7.2(a) and 7.2(b) were not satisfied and were incapable of being satisfied. Accordingly, Veridian has not met, and cannot meet, the contractual prerequisite for seeking specific performance, and any claim for specific performance must be denied.
93. Even apart from the contractual limitation in SPA Section 10.12, specific performance is an extraordinary equitable remedy that lies within the sound discretion of this Court. Specific performance should not be granted where, as here, the Buyer has lawfully terminated the agreement pursuant to an express contractual termination right, the closing conditions to the Buyer's obligations were not satisfied, and the equities do not favor compelled performance.
94. The impracticability of specifically enforcing the closing of a terminated $900,000,000 acquisition of a clinical-stage biotechnology company whose sole material drug candidate is subject to an active FDA clinical hold further counsels against the exercise of the Court's equitable discretion. Compelling Penterra to close the acquisition of a company in these circumstances — paying $900,000,000 for a company whose lead asset has suffered a catastrophic clinical failure, whose prospects for regulatory approval are at best uncertain and at worst nonexistent, and whose independent DMC and the FDA have both taken extraordinary safety-related actions — would be inequitable and contrary to the reasonable expectations of both parties at the time of contracting.
SEVENTH AFFIRMATIVE DEFENSE: Reverse Termination Fee Is Inapplicable
95. To the extent Veridian claims entitlement to the reverse termination fee of Forty-Five Million Dollars ($45,000,000), such claim is barred because the reverse termination fee provision in the SPA is triggered exclusively by a failure of Buyer's financing, and Buyer's financing did not fail.
96. The SPA provides for the payment of the reverse termination fee only in the specifically defined circumstance where the Buyer fails to consummate the closing because the financing contemplated by the financing commitment letter is not available to the Buyer on the terms set forth therein, and such financing failure is the proximate cause of the Buyer's failure to close.
97. Penterra's financing was fully committed and available at all relevant times:
(a) The $500,000,000 term loan commitment from Summit Ridge Capital Partners, LP and Ironclad Trust Company, N.A. (Reference No. CL-2024-PPCA-0607) remained in full force and effect and was not terminated, withdrawn, or otherwise impaired at the time of Penterra's termination of the SPA.
(b) Penterra had designated $400,000,000 of its own cash to fund the balance of the purchase price, drawn from total cash and cash equivalents on hand of approximately $2.1 billion as of the end of Q2 2024.
(c) The aggregate available funding of $900,000,000 ($500,000,000 committed term loan plus $400,000,000 cash) was fully sufficient to pay the entire purchase price.
98. Penterra's termination of the SPA had nothing whatsoever to do with financing. The termination was based solely on the failure of the closing conditions in SPA Sections 7.2(a) and 7.2(b) due to the occurrence of a material adverse effect. The reverse termination fee is therefore inapplicable as a matter of contract.
EIGHTH AFFIRMATIVE DEFENSE: Failure to Mitigate Damages